Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: A Kansai Clinical Oncology Group study (KCOG9812)

Taniguchi, Hiroshi; Itani, Yoshio; Ito, Kimihiko; Kanazawa, Riichiro; Toyoda, Shinji; Takeuchi, Satoshi

doi:10.1016/j.ygyno.2012.10.001

Cited by 5 publications

(5 citation statements)

References 41 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given our data, peritoneal cytology at IS provides us with additional information with which to predict PFS in individual cases, as well as reconsider post‐IS adjuvant chemotherapy regimens for cytology‐positive cases. Recent reports from Japan have demonstrated that i.p., versus i.v., administration of chemotherapy was more effective in ovarian cancer cases in which IDS ended with suboptimal surgery (KCOG9812) . Cytology‐positive cases may warrant either change of regimen or route of administration for post‐IS adjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Recent reports from Japan have demonstrated that i.p., versus i.v., administration of chemotherapy was more effective in ovarian cancer cases in which IDS ended with suboptimal surgery (KCOG9812). 29 Cytology-positive cases may warrant either change of regimen or route of administration for post-IS adjuvant chemotherapy. Obviously, randomized well-designed prospective studies are warranted to investigate new strategies for post-IS adjuvant chemotherapy in peritoneal cytology-positive cases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: A retrospective study

Nagasaka

Kawana

Tomio

et al. 2014

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: A retrospective study

Nagasaka

Kawana

Tomio

et al. 2014

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…The first-line regimen was decided based on our clinical trial, and the latter two regimens were used in other clinical trials. [2][3][4] No radiological or serological response was observed after the first-or third-line regimens and the efficacy of the second-line regimen was not evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…This patient with stage IIIC disease received three lines of chemotherapy; first‐line cisplatin and carboplatin, second‐line gemcitabine and docetaxel, and third‐line irinotecan and carboplatin. The first‐line regimen was decided based on our clinical trial, and the latter two regimens were used in other clinical trials 2–4 . No radiological or serological response was observed after the first‐ or third‐line regimens and the efficacy of the second‐line regimen was not evaluated.…”

Section: Discussionmentioning

confidence: 99%

Fertility‐sparing management of stage IIIC serous borderline ovarian tumor: A case report of a 20‐year follow‐up

Iwamoto¹,

Tsubamoto²,

Yoshiyasu³

et al. 2023

J of Obstet and Gynaecol

Self Cite

View full text Add to dashboard Cite

Multimodal treatment, including assisted reproductive technology, is necessary in young patients with advanced borderline ovarian tumors. However, the details of long‐term follow‐up cases have not been reported. In this report, a 19‐year‐old patient presented with a stage IIIC serous borderline tumor. The patient underwent five fertility‐sparing surgeries. The tumor did not respond to any of the three lines of chemotherapy administered. Serological and radiological responses were observed following hormonal treatment with leuprorelin, followed by a fourth surgery. Before the planned fifth surgery for complete resection of both adnexa, cryopreservation of the fertilized eggs was performed. At age 36, when the disease‐free interval exceeded the previous one, we proposed embryo transfer; however, she declined fertility treatment. The patient had developed rheumatoid arthritis and childbirth not a priority. The patient had lived without any evidence of disease for 7 years following the last surgery and 20 years after the initial visit.

show abstract

“…chemotherapy (delivered by means of abdominal catheters). 34 , 35 We thus considered NACT as an important component for our study protocol involving HIPEC.…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach

Batista

Carneiro

Tancredi

et al. 2017

CMAR

View full text Add to dashboard Cite

PurposeHyperthermic intraperitoneal chemotherapy (HIPEC) has been considered a promising treatment option for advanced or recurrent ovarian cancer, but there is no clear evidence based on randomized controlled trials to advocate this approach as a standard therapy. In this study, we aim to present the early outcomes and insights after an interim analysis of a pioneering clinical trial in Brazil.MethodsThis study was a cross-sectional analysis of early data from our ongoing clinical trial – an open-label, double-center, single-arm trial on the safety and efficacy of using HIPEC for advanced ovarian cancer (ClinicalTrials.gov: NCT02249013). A fast-track recovery strategy was also applied to improve patient outcomes.ResultsNine patients with stage IIIB (n=1) or IIIC (n=8) epithelial malignancies were enrolled until February 2017. The median (range) serum CA125 level at diagnosis was 692 (223.7–6550) U/mL. The median number of preoperative cycles of intravenous (i.v.) chemotherapy was 3 (2–4), resulting in peritoneal cancer index scores of 9 (3–18) at the time of HIPEC. Time of restarting i.v. chemotherapy was 37 (33–50) days with all patients completing 6 cycles as planned. The median operation time was 395 (235–760) minutes, the length of hospital stay was 4 (3–10) days, and all the patients left the ICU on the morning after the procedure. Two patients experienced no postoperative complications, whereas 91% of the complications were minor G1/G2 events. Preliminary assessment also suggested no impairment of the patient’s quality of life.ConclusionOur comprehensive protocol might represent a promising all-in-one approach for advanced ovarian cancer. The patient recruitment for this trial is ongoing.

show abstract

Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: A Kansai Clinical Oncology Group study (KCOG9812)

Cited by 5 publications

References 41 publications

Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: A retrospective study

Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: A retrospective study

Fertility‐sparing management of stage IIIC serous borderline ovarian tumor: A case report of a 20‐year follow‐up

Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach

Contact Info

Product

Resources

About